drugset / Trial / NCT06290687

Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy

NCT06290687

Phase 2 Recruiting 40 enrolled Case Comprehensive Cancer Center
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to determine if a partial cystectomy with extended pelvic lymph node removal will be effective at treating Muscle-Invasive Bladder Cancer instead of a complete cystectomy with extended pelvic lymph node removal. This clinical trial aims to determine the safety and oncologic efficacy of the intervention, and to examine patient-reported quality of life outcomes in participants. Participants will receive the standard pre-surgery treatment for approximately 4 to 6 weeks. After the pre-surgery treatment is completed, participants will undergo a partial cystectomy with extended pelvic lymph node dissection. After surgery, participants will receive adjuvant systemic therapy.

Timeline

Start
2026-07
Primary completion
2026-12-29
Completion
2027-12-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified
Subject Doxorubicin Other / unclassified
Subject Gemcitabine Small molecule
Subject Methotrexate Small molecule
Subject Vinblastine Small molecule